You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Functional genomics firm The DNA Company acquired digital therapeutics app My Pain Sensei, giving it an AI development platform and a Health Canada medical device license.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In PLOS this week: alternatively spliced form of FBXO38 contributes to chronic obstructive pulmonary disease, evolution of the avian influenza virus H9N2, and more.
The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.
University College London researchers sequenced a woman who realized late in life that she could not feel pain, Gizmodo reports.
Two research teams find a role for PIEZO2 in touch sensitivity after injury and inflammation.
These three loci implicated skeletal and spinal cord development-linked pathways in chronic back pain.
After a series of duplication and rearrangement events, the genes involved in two key pathways producing morphine, codeine, and noscapine have clustered in the genome.
The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.
The team said that by understanding why some members of this family don't feel pain, they could unearth new drug targets to treat others with chronic pain.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.